Pacad Investment Ltd. boosted its stake in shares of Cambrex Corporation (NYSE:CBM) by 1,233.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,000 shares of the biotechnology company’s stock after purchasing an additional 3,700 shares during the quarter. Pacad Investment Ltd.’s holdings in Cambrex Corporation were worth $239,000 at the end of the most recent reporting period.
A number of other large investors also recently added to or reduced their stakes in the stock. Mark Sheptoff Financial Planning LLC boosted its position in Cambrex Corporation by 2.5% during the 2nd quarter. Mark Sheptoff Financial Planning LLC now owns 4,000 shares of the biotechnology company’s stock valued at $239,000 after purchasing an additional 99 shares during the period. Scout Investments Inc. boosted its position in Cambrex Corporation by 11.2% during the 2nd quarter. Scout Investments Inc. now owns 80,525 shares of the biotechnology company’s stock valued at $4,811,000 after purchasing an additional 8,100 shares during the period. Intrust Bank NA boosted its position in Cambrex Corporation by 3.5% during the 2nd quarter. Intrust Bank NA now owns 8,693 shares of the biotechnology company’s stock valued at $519,000 after purchasing an additional 292 shares during the period. Bridge City Capital LLC acquired a new position in Cambrex Corporation during the 2nd quarter valued at approximately $1,932,000. Finally, JW Asset Management LLC boosted its position in Cambrex Corporation by 11.0% during the 2nd quarter. JW Asset Management LLC now owns 50,519 shares of the biotechnology company’s stock valued at $3,019,000 after purchasing an additional 5,000 shares during the period. Institutional investors and hedge funds own 98.28% of the company’s stock.
In other Cambrex Corporation news, CEO Steven M. Klosk sold 12,000 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $61.39, for a total value of $736,680.00. Following the transaction, the chief executive officer now directly owns 95,328 shares in the company, valued at approximately $5,852,185.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 36,000 shares of company stock worth $2,070,960 over the last quarter. Corporate insiders own 2.48% of the company’s stock.
Cambrex Corporation (CBM) opened at 50.45 on Tuesday. Cambrex Corporation has a 12 month low of $38.30 and a 12 month high of $62.95. The firm’s 50-day moving average price is $54.45 and its 200-day moving average price is $55.26. The firm has a market cap of $1.65 billion, a price-to-earnings ratio of 18.38 and a beta of 2.25.
Cambrex Corporation (NYSE:CBM) last announced its quarterly earnings data on Friday, August 4th. The biotechnology company reported $0.76 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.76. The firm had revenue of $134.55 million for the quarter, compared to analyst estimates of $136.82 million. Cambrex Corporation had a return on equity of 24.25% and a net margin of 17.70%. The business’s quarterly revenue was up 13.4% compared to the same quarter last year. During the same period last year, the company earned $0.68 EPS. Equities research analysts predict that Cambrex Corporation will post $3.08 earnings per share for the current year.
A number of research analysts recently issued reports on the company. ValuEngine lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub lowered Cambrex Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, August 24th. Finally, Zacks Investment Research lowered Cambrex Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $64.00.
Cambrex Corporation Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.